Biocure Technology Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing biosimilar technologies for cancer treatment. The Companyâ€™s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.

Employees

Sector

Pharmaceuticals

More about the company

Market Closed - Canadian Securities Exchange 11:46:42 2026-07-29 EDT			5-day change	1st Jan Change
0.0550 ^CAD	-21.43%		-.--%	-26.67%

08-28	Biocure Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-21	Glorious Success Limited signed a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE.X) for in a reverse merger transaction.	CI

Market Cap	1.11M 799K 692K 654K 592K 76.6M 1.12M 7.81M 3M 38.84M 3M 2.93M 124M	P/E 2024	-0.6x	P/E 2025	-11.5x
Enterprise Value	1.13M 811K 702K 664K 601K 77.79M 1.14M 7.93M 3.05M 39.45M 3.05M 2.98M 126M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	96.58%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Canadian Securities Exchange	CURE.X	Delayed
Deutsche Boerse AG	1WH0	Delayed

08-28	Biocure Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-21	Glorious Success Limited signed a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE.X) for in a reverse merger transaction.	CI
04-15	Biocure Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-13	Biocure Technology Inc. Auditor Raises 'Going Concern' Doubt	CI
11-28	Biocure Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-26	Biocure Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-30	Biocure Technology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-05-29	Biocure Technology Inc. announced that it has received CAD 0.1 million in funding	CI
25-05-02	Biocure Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-05-02	Biocure Technology Inc. Auditor Raises 'Going Concern' Doubt	CI
25-04-20	Biocure Technology Inc. cancelled the transaction announced on December 19, 2024	CI
25-04-20	Biocure Technology Inc. announced that it expects to receive CAD 0.15 million in funding	CI
24-12-18	Biocure Technology Inc. announced that it expects to receive CAD 0.2 million in funding	CI

Biocure Technology Inc. Stock

Stocks

CURE.X

CA09075T2065

Pharmaceuticals

Valuation: Biocure Technology Inc.

Chart: Biocure Technology Inc.

Latest news: Biocure Technology Inc.

Press Releases: Biocure Technology Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Biocure Technology Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

08-12	Biocure Technology Inc. enters into Definitive Share Exchange Agreement to acquire Glorious Success Limited	AQ
08-11	Canadian Investment Regulatory Organization Trading Halt - CURE.X	AQ
06-23	Canadian Investment Regulatory Organization Trade Resumption - CURE.X	AQ
06-22	Canadian Investment Regulatory Organization Trading Halt - CURE.X	AQ
24-10-23	CSE Bulletin: Consolidation - Biocure Technology Inc. (CURE.X)	NE

1 day	-21.43%
3 months	+37.50%
6 months	+57.14%
Current year	-26.67%

Current year	0.04	0.09
1 year	0.03	0.24
3 years	0.01	0.32
5 years	0.01	1.94
10 years	0.01	17.01

Manager	Title	Age	Since
Yee Sing Cheng CEO	Chief Executive Officer	44	2023-09-07
Konstantin Lichtenwald DFI	Director of Finance/CFO	42	2018-02-28

Director	Title	Age	Since
Collin Kim BRD	Director/Board Member	60	2015-08-27
Konstantin Lichtenwald BRD	Director/Board Member	42	2018-02-28
Yee Sing Cheng BRD	Director/Board Member	44	2023-09-07

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
7/8/25	Simon Cheng	Sell		500,000	4.7872%
7/8/25	Simon Cheng	Other		0	0%	-
7/8/25	Collin Kim	Sell	Director	1,600,000	15.3191%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOCURE TECHNOLOGY INC.	-21.43%	-.--%	+10.00%	-59.26%	799K
ELI LILLY AND COMPANY	-0.19%	+1.09%	+51.85%	+97.36%	1,013B
JOHNSON & JOHNSON	+0.33%	-0.71%	+50.62%	+65.50%	644B
ABBVIE INC.	+0.49%	+5.73%	+20.88%	+72.92%	465B
ROCHE HOLDING AG	-0.22%	+2.88%	+38.48%	+37.98%	352B
NOVARTIS AG	-0.07%	+1.82%	+16.57%	+23.39%	264B
ASTRAZENECA PLC	-0.31%	+2.02%	+6.15%	+10.75%	253B
AMGEN INC.	-1.53%	-4.46%	+36.90%	+44.08%	203B
NOVO NORDISK A/S	-1.60%	-5.51%	-22.30%	-58.60%	188B
GILEAD SCIENCES, INC.	+0.49%	-0.23%	+30.00%	+93.34%	181B
Average	-2.22%	-0.98%	+23.91%	+32.74%	356.37B
Weighted average by Cap.	+0.41%	+0.01%	+34.52%	+59.42%

	2024	2025
Net sales	-	-
Net income	-262K -189K -163K -154K -140K -18.09M -264K -1.84M -709K -9.17M -708K -693K -29.25M	-103K -73.91K -64.02K -60.54K -54.81K -7.09M -104K -722K -278K -3.59M -278K -271K -11.46M
Net Debt	31.65K 22.74K 19.7K 18.63K 16.86K 2.18M 31.89K 222K 85.52K 1.11M 85.42K 83.53K 3.53M	17.3K 12.43K 10.76K 10.18K 9.22K 1.19M 17.43K 121K 46.73K 604K 46.68K 45.64K 1.93M